乳腺癌新辅助化疗的临床评价方法解析  

Clinical Evaluation of Neoadjuvant Chemotherapy in Patients with Breast Cancer

作　　者：韩芸蔚[1] 温绍艳[1] 刘伟[1] 王欣[1] 

机构地区：[1]乳腺癌防治教育部重点实验室,天津市肿瘤防治重点实验室,天津医科大学附属肿瘤医院乳腺一科,天津市300060

出　　处：《中国肿瘤临床》2011年第7期415-418,共4页Chinese Journal of Clinical Oncology

摘　　要：乳腺癌新辅助化疗(NAC)最初是指对局部晚期乳腺癌患者手术治疗之前所进行的辅助化疗,目前己将该治疗扩展至肿瘤较大的可手术的乳腺癌患者,以使肿瘤降期,进而达到保乳手术治疗的目的。随着新辅助化疗在乳腺癌患者中不断推广应用,使用传统方法和影像学评价预测新辅助化疗反应,未能提供准确和可靠的数据。因此临床实践中迫切需要一种能准确评价化疗后肿瘤变化的检查方法。最近,光散射断层成像,新的生物标志物,癌基因组分析引入到临床实践,产生了初步可喜的成果。本文对乳腺癌新辅助化疗的临床评价方法进行综述。Neoadjuvant chemotherapy for breast cancer （BC） has been used as an initial treatment for patients with locally advanced BC before surgical resection. The use of this therapy has now been extended to patients with operable BC in an attempt to down-stage the tumors in order to successfully perform breast-conserving surgery. Traditional methods and image evaluation for predicting the effect of neoadjuvant chemotherapy have failed to provide accurate and reliable data. Therefore, a method of examination that can correctly assess the tumor changes after chemotherapy is urgently needed in clinical practice. Recently, light scattering laminagraphy, new biological markers and analysis of cancer genomes have been introduced to clinical practice, achieving promising preliminary outcomes. In this article, the clinical assessment of neoadjuvant chemotherapy for BC was reviewed.

关 键 词：乳腺癌 新辅助化疗 影像学 

分 类 号：R737.9[医药卫生—肿瘤]